Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07311356

Prognosis of Early-onset Anorexia Nervosa

Evalutation of the Prognosis and Quality of Life of Patients Hospitalized for Early-onset Anorexia Nervosa

Status
Recruiting
Phase
Study type
Observational
Enrollment
140 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
0 Years – 30 Years
Healthy volunteers
Not accepted

Summary

The AM2P study aims to evaluate the long-term prognosis and quality of life of patients with early-onset anorexia nervosa, assessed 4 to 9 years after hospitalization. Prognosis will be determined using a composite outcome measure based on questionnaire responses and health indicators, including body mass index (BMI). In addition, the study will examine the patients' overall physical condition both at the time of assessment and during the interval between their last hospitalization and the present evaluation.

Detailed description

This study includes all patients who were hospitalized at Robert Debré Hospital in Paris between 2016 and 2021 for early-onset anorexia nervosa. During follow-up interviews, participants will complete a standardized set of questionnaires assessing their mental and physical health (EDE-Q, PHQ-9, MSI-BPD, GAD-7, and SF-12). The primary outcome is the evaluation of the severity of the eating disorder, measured with the EDE-Q. Secondary outcomes will be derived from the additional questionnaires and will include body mass index (BMI), menstrual status, follow-up data, general well-being, impact of the eating disorder, hospital readmission, suicide attempts, depressive symptoms, borderline personality traits, anxiety, quality of life, educational attainment, occupational status, and treatments received. We hypothesize that approximately 50% of patients will achieve remission three years after hospitalization.

Conditions

Timeline

Start date
2025-12-05
Primary completion
2026-03-31
Completion
2026-03-31
First posted
2025-12-30
Last updated
2026-02-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07311356. Inclusion in this directory is not an endorsement.